Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

Veronica Galvan; Jorge Quarleri

doi:10.1007/s11357-021-00501-3

Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

Veronica Galvan, Jorge Quarleri

Research output: Contribution to journal › Editorial › peer-review

Abstract

Vaccine development has become the main tool for reducing COVID-19 cases and the severity of the disease. Comparative analyses of adaptive immunity generated by different vaccines platforms are urgently needed. Multiple studies have compared different vaccines using similar platforms; however, comparative analyses of vaccines across different platforms are lacking. This Editorial provides a summary and commentary on the main findings reported in the observational and longitudinal study by Vályi-Nagy et al. (Geroscience 43:2321) that compared the adaptive (humoral and T cell-mediated) immune responses elicited by Sinopharm and BNT162b2 vaccines against SARS-CoV-2 virus among 57 healthy adult Hungarian volunteers.

Original language	English (US)
Pages (from-to)	57-61
Number of pages	5
Journal	GeroScience
Volume	44
Issue number	1
DOIs	https://doi.org/10.1007/s11357-021-00501-3
State	Published - Feb 2022
Externally published	Yes

ASJC Scopus subject areas

Aging
veterinary (miscalleneous)
Complementary and alternative medicine
Geriatrics and Gerontology
Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11357-021-00501-3

Cite this

@article{7aefb1e58bdd4364b8e71b563f4c13f7,

title = "Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans",

abstract = "Vaccine development has become the main tool for reducing COVID-19 cases and the severity of the disease. Comparative analyses of adaptive immunity generated by different vaccines platforms are urgently needed. Multiple studies have compared different vaccines using similar platforms; however, comparative analyses of vaccines across different platforms are lacking. This Editorial provides a summary and commentary on the main findings reported in the observational and longitudinal study by V{\'a}lyi-Nagy et al. (Geroscience 43:2321) that compared the adaptive (humoral and T cell-mediated) immune responses elicited by Sinopharm and BNT162b2 vaccines against SARS-CoV-2 virus among 57 healthy adult Hungarian volunteers.",

author = "Veronica Galvan and Jorge Quarleri",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to American Aging Association.",

year = "2022",

month = feb,

doi = "10.1007/s11357-021-00501-3",

language = "English (US)",

volume = "44",

pages = "57--61",

journal = "GeroScience",

issn = "2509-2715",

publisher = "Springer International Publishing AG",

number = "1",

}

TY - JOUR

T1 - Editorial

T2 - Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

AU - Galvan, Veronica

AU - Quarleri, Jorge

PY - 2022/2

Y1 - 2022/2

N2 - Vaccine development has become the main tool for reducing COVID-19 cases and the severity of the disease. Comparative analyses of adaptive immunity generated by different vaccines platforms are urgently needed. Multiple studies have compared different vaccines using similar platforms; however, comparative analyses of vaccines across different platforms are lacking. This Editorial provides a summary and commentary on the main findings reported in the observational and longitudinal study by Vályi-Nagy et al. (Geroscience 43:2321) that compared the adaptive (humoral and T cell-mediated) immune responses elicited by Sinopharm and BNT162b2 vaccines against SARS-CoV-2 virus among 57 healthy adult Hungarian volunteers.

AB - Vaccine development has become the main tool for reducing COVID-19 cases and the severity of the disease. Comparative analyses of adaptive immunity generated by different vaccines platforms are urgently needed. Multiple studies have compared different vaccines using similar platforms; however, comparative analyses of vaccines across different platforms are lacking. This Editorial provides a summary and commentary on the main findings reported in the observational and longitudinal study by Vályi-Nagy et al. (Geroscience 43:2321) that compared the adaptive (humoral and T cell-mediated) immune responses elicited by Sinopharm and BNT162b2 vaccines against SARS-CoV-2 virus among 57 healthy adult Hungarian volunteers.

UR - http://www.scopus.com/inward/record.url?scp=85121489975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121489975&partnerID=8YFLogxK

U2 - 10.1007/s11357-021-00501-3

DO - 10.1007/s11357-021-00501-3

M3 - Editorial

C2 - 34935099

AN - SCOPUS:85121489975

VL - 44

SP - 57

EP - 61

JO - GeroScience

JF - GeroScience

SN - 2509-2715

IS - 1

ER -

Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this